(Q34590306)

3 August 2017

1 reference

title

The emerging role of MRI in multiple sclerosis and the new diagnostic criteria (English)

1 reference

3 August 2017

0 references

H F McFarland

1 reference

3 August 2017

publication date

1 February 2002

1 reference

Multiple Sclerosis Journal

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

71-72

1 reference

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Surrogate markers in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Impact of nuclear magnetic resonance imaging on the assessment of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Multisequence MRI in clinically isolated syndromes and the early development of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

From enhancing lesions to brain atrophy in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Imaging axonal damage of normal-appearing white matter in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

One year follow up study of primary and transitional progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Magnetization transfer imaging of patients with definite MS and negative conventional MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Natural history of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Axonal damage in acute multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Axonal Transection in the Lesions of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Total brain N-acetylaspartate: a new measure of disease load in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Correlation of volumetric magnetization transfer imaging with clinical data in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Magnetization transfer contrast (MTC) and long repetition time spin-echo MR imaging in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458502MS767XX

10.1191/1352458502MS767XX

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference